Last edition
News about "bispecific antibody"
Merus, Halozyme Partner to Develop Subcutaneous Petosemtamab
Under the agreement, Merus will pay Halozyme upfront and milestone-based payments, with Halozyme also eligible for low- to mid-single-digit royalties on future ENHANZE-enabled petosemtamab sales.
Bispecific Antibody | 19/11/2025 | By Dineshwori
Johnson and Johnson to Obtain Rights to Clinical-Stage Bispecific Antibody
Johnson & Johnson has signed a definitive deal with Numab Therapeutics, to acquire from Numab’s shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26.
Bispecific Antibody | 30/05/2024 | By Aishwarya | 260
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy